The third generation of TPO mimetics are again biologics
After failure of 1st generation thrombopoietic growth factors due to immunogencity, the 2nd generation is focused on oral TPO mimetics, now followed by a 3rd generation of engineered biologics with potential for higher potency and efficacy
14-Aug-2008 -
The Business Intelligence firm La Merie S.L. reported in its most recent pipeline update of thrombopoiesis stimulating agents that eight thrombopoietin (TPO) mimetics are in clinical stages of development. The two most advanced are close to FDA's decision on the marketing application. Due to ...
antibodies
biologics
chemotherapy
+7